Skip to main content

Table 2 Microbiological outcomes and side effects for patients, by province

From: Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study

  Hanoi province Thanh Hoa province Total
Total n = 494 n = 168 n = 662
Treatment duration [median (IQR)]
 Start to completion (months) 19.0 (9.8–20.0) 20.0 (9.7–21.3) 19.0 (9.7–20.0)
 Inpatient regimen (days) 25 (16–34) 33 (19–42) 28 (16–37)
Smear conversion after 2 months n = 454 n = 132 n = 586
 Yes 418 (92.1%) 85 (64.4%) 503 (85.8%)
 No 36 (7.9%) 47 (35.6%) 83 (14.2%)
 Not reported 40 36 76
Smear conversion after 4 months n = 421 n = 116 n = 537
 Yes 409 (97.1%) 110 (94.8%) 519 (96.6%)
 No 12 (2.9%) 6 (5.2%) 18 (3.4%)
 Not reported 73 52 125
Culture conversion after 2 months n = 448 n = 105 n = 553
 Yes 405 (90.4%) 10 (9.5%) 415 (75.0%)
 No 43 (9.6%) 95 (90.5%) 138 (25.0%)
 Not reported 46 63 109
Culture conversion after 4 months n = 420 n = 108 n = 528
 Yes 402 (95.7%) 86 (79.6%) 488 (92.4%)
 No 18 (4.3%) 22 (20.4%) 40 (7.6%)
 Not reported 74 60 134
Side effects during treatment
 At least one inpatient side effect reported n = 308 n = 144 n = 452
  Yes 23 (7.5%) 16 (11.1%) 39 (8.6%)
  No 285 (92.5%) 128 (88.9%) 413 (91.4%)
  Not reported 186 24 210
 At least one outpatient side effect reported n = 447 n = 125 n = 572
  Yes 75 (16.8%) 32 (25.6%) 107 (18.7%)
  No 372 (83.2%) 93 (74.4%) 465 (81.3%)
  Not reported 47 43 90
 Outpatient side effects reporteda n = 195 n = 52 n = 247
  Blood disorder 6 (3.1%) 0 (0%) 6 (2.4%)
  Bowel pain 3 (1.5%) 2 (3.8%) 5 (2.0%)
  Hearing loss 9 (4.6%) 3 (5.8%) 12 (4.9%)
  Hepatotoxicity 35 (17.9%) 0 (0%) 35 (14.2%)
  High blood sugar 10 (5.1%) 0 (0%) 10 (4.0%)
  High uric acid 42 (21.5%) 0 (0%) 42 (17.0%)
  Hypokalemia 15 (7.7%) 0 (0%) 15 (6.1%)
  Joint pain 19 (9.7%) 16 (30.8%) 35 (14.2%)
  Loss of appetite 11 (5.6%) 0 (0%) 11 (4.5%)
  Nephrotoxicity 17 (8.7%) 0 (0%) 17 (6.9%)
  Neurotoxicity 7 (3.6%) 1 (1.9%) 8 (3.2%)
  Nausea 0 (0%) 23 (44.2%) 23 (9.3%)
  Vision loss 7 (3.6%) 2 (3.8%) 9 (3.6%)
  Vertigo 14 (7.2%) 5 (9.6%) 19 (7.7%)
  Not reported 299 116 415
  1. Bolded numbers indicate the number of individuals for whom data were available (percentages exclude those for whom data were not reported)
  2. aPatients could report more than one side effect